Related Experiment Video
Updated: Mar 13, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Long-term control for > 9 years with megestrol acetate-letrozole: metastatic endometrioid carcinoma case report
Lixia Liu1, Lina Ma1, Lu Yang2
1Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Shanxi, Taiyuan, China.
Background:
Hormone receptor-positive (HR+) endometrial carcinoma (EC) responds to endocrine therapy, but clinical benefit duration is often limited, especially in patients with widely metastatic or recurrent disease.
Case:
A 54-year-old woman with HR-high (ER/PR 90%) metastatic EC (FIGO IIIC2) discontinued adjuvant chemotherapy due to severe toxicity. She initiated megestrol acetate and letrozole in March 2017, achieving stable disease (SD) for 38 months. Self-discontinuation (January-July 2020) led to disease progression (new retroperitoneal lymph nodes), but resuming full-dose therapy restored SD for 49 months. After dose reduction (July 2023), the disease progressed again at 12 months; re-escalation to full dose induced regression. At last follow-up (OS: 108 months), she maintained SD with minimal toxicity.
Conclusion:
This is the first case demonstrating that full-dose megestrol acetate plus letrozole may induce durable antitumor activity in HR-high expression metastatic EC, warranting prospective validation.
Related Concept Videos
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
02:38Mitogens and the Cell Cycle
02:56Treatment Resistant Cancers